CTMX — CytomX Therapeutics Share News
0.000.00%
Last trade - 00:00- $531.67m
- $201.39m
- $76.20m
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
CytomX rises on expanded Regeneron deal worth up to $4 billion
U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics
CytomX rises on expanded Regeneron deal with up to $4 billion in milestones
CytomX Q1 revenue falls but beats analyst expectations
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
CytomX drops on $250 mln equity raise
Brief: CytomX Therapeutics Prices Public Offering Of 45,990,567 Shares At $5.30 Per Share
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
CytomX retreats ahead of planned $250 mln equity raise after promising cancer drug data
Brief: CytomX Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: CytomX Therapeutics Inc Files For Mixed Shelf Offering, Size Not Disclosed - SEC Filing
CytomX dips after launching stock offering following colorectal cancer drug data
CytomX jumps on promising trial data for colorectal cancer drug
Brief: Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer